Health In Tech, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health In Tech, Inc. (Nasdaq: HIT) on September 24, 2025. The report discloses a corporate governance event regarding executive compensation approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific executive compensation arrangement and does not contain financial performance data.
Material Changes
The material change disclosed is the grant of Restricted Stock Awards (RSAs) to two named executive officers in connection with a new corporate initiative:
- Tim Johnson (CEO): Granted 80,000 shares of restricted stock.
- Linlin (Julia) Qian (CFO): Granted 80,000 shares of restricted stock.
Guidance, Outlook, and Management Commentary
The RSAs are tied to the development and launch of a new "Initiative." The vesting schedule is performance-based and divided into three equal tranches:
- Tranche 1 (1/3): Vests in equal monthly installments over 12 months commencing on the date a letter of intent or memorandum of understanding is signed.
- Tranche 2 (1/3): Vests in equal monthly installments over 12 months commencing on the date the Initiative enters proof-of-concept or beta launch.
- Tranche 3 (1/3): Vests in equal monthly installments over 12 months commencing on the date of the full commercial launch of the Initiative.
The awards were granted pursuant to the Health In Tech, Inc. Equity Incentive Plan. The filing does not provide specific financial guidance or discuss other risks beyond the standard terms of the award agreements.
Investor Verification Checklist
- Verify the specific details and milestones of the "Initiative" referenced in the vesting schedule.
- Review the Restricted Stock Award Agreements for additional forfeiture conditions or performance metrics not detailed in this summary.
- Confirm the total outstanding share count and potential dilution impact of the 160,000 new shares granted.
- Monitor future filings for updates on the signing of the letter of intent or memorandum of understanding to trigger the first vesting tranche.